EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

Animesh Sinha iD, Roland Klebe iD, Michael L Rekart, Jose Luis Alvarez, Alena Skrahina, Natalia Yatskevich iD, Varvara Solodovnikova, Dzmitry Viatushka, Nargiza Parpieva, Khasan Safaev, Irina Liverko, Zinaida Tigay und 13 weitere

Clinical Infectious Diseases · 06.11.2025 · 81 (4) · 838-845

DOI: 10.1093/cid/ciaf035 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 18.02.2025. Verfasst von Animesh Sinha und 24 weiteren Autor:innen. Beteiligte Einrichtung: Médecins Sans Frontières, London, United Kingdom. Hauptthemen laut MEDLINE: Linezolid, Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Diarylquinolines. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, Global Fund, Médecins Sans Frontières.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Week all-oral bedaquiline, pretomanid, and linezolid (BPaL)–based regimens have demonstrated higher rates of treatment success and have been recommended by the World Health Organization. Operational research is urgently required to evaluate these regimens in non-trial settings.

Methods

This was a prospective cohort study of patients with microbiologically confirmed MDR/RR-TB and pre–extensively drug-resistant TB (pre-XDR-TB) initiated on BPaL-based regimens in Belarus and Uzbekistan (February 2022–June 2023). All clinical care and research procedures were delivered by treating physicians. After treatment completion, patients were followed up at 6 and 12 months, including collecting sputum to ascertain recurrence. The primary objective was to estimate the effectiveness (cured or treatment completed) and safety (the occurrence of serious adverse events) of BPaL-based regimens.

Results

A total of 677 patients initiated treatment with BPaL-based regimens during the study. We documented successful treatment outcomes in 95.3% (427/448) of patients with MDR/RR-TB treated with BPaL plus moxifloxacin and 90.4% (207/229) of patients with pre–XDR-TB treated with BPaL plus clofazimine. 10.2% (69/677) experienced serious adverse events including 24 deaths (3.5%), 11 of which occurred during treatment. 83.3% (20/24) of deaths were not related to TB or TB treatment. Of patients who were successfully treated and completed 12-month follow-up, 0.5% (2/383) had recurrence.

Conclusions

BPaL-based regimens for MDR/RR-TB and pre–XDR-TB are safe and highly effective in non-trial settings. These regimens should be considered for widespread implementation globally, and further research is needed to evaluate their performance in other key populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidAntitubercular AgentsTuberculosis, Multidrug-ResistantDiarylquinolinesNitroimidazolesHumansProspective StudiesFemaleMaleAdultMiddle AgedRifampinUzbekistanRepublic of BelarusTreatment OutcomeDrug Therapy, CombinationYoung AdultMycobacterium tuberculosis

Stichwörter der Autor:innen

BPaLBPaLMMDR-TBRR-TBpre–XDR-TB

Substanzen

LinezolidAntitubercular AgentsbedaquilineDiarylquinolinesRifampinNitroimidazoles

Autor:innen und Institutionen

  • Médecins Sans Frontières, London, United Kingdom.
  • Médecins Sans Frontières, Berlin, Germany.
  • Médecins Sans Frontières, Tashkent, Uzbekistan.
  • Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus.
  • Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology, Tashkent, Uzbekistan.
  • Republican Center of Tuberculosis and Pulmonology, Nukus, Uzbekistan.

ORCID-Profile: Animesh Sinha, Roland Klebe, Natalia Yatskevich, Soe Moe, Muzaffar Achilov, Nazgul Samieva, Norman Sitali

Förderung

  • World Health Organization
  • Global Fund
  • Médecins Sans Frontières

Zitieren

APA

Sinha, A., Klebe, R., Rekart, M. L., Alvarez, J. L., Skrahina, A., Yatskevich, N., Solodovnikova, V., Viatushka, D., Parpieva, N., Safaev, K., Liverko, I., Tigay, Z., Moe, S., Khristusev, A., Allamuratova, S., Mirzabaev, S., Achilov, M., Samieva, N., Lachenal, N., …, & Saunders, M. J. (2025). The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan. Clinical Infectious Diseases, 81(4), 838-845. https://doi.org/10.1093/cid/ciaf035

Vancouver

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, Yatskevich N, et al. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan. Clinical Infectious Diseases. 2025;81(4):838-845. doi:10.1093/cid/ciaf035

BibTeX
@article{Sinha2025,
  author = {Sinha, Animesh and Klebe, Roland and Rekart, Michael L and Alvarez, Jose Luis and Skrahina, Alena and Yatskevich, Natalia and Solodovnikova, Varvara and Viatushka, Dzmitry and Parpieva, Nargiza and Safaev, Khasan and Liverko, Irina and Tigay, Zinaida and Moe, Soe and Khristusev, Aleksandr and Allamuratova, Sholpan and Mirzabaev, Sanjar and Achilov, Muzaffar and Samieva, Nazgul and Lachenal, Nathalie and Merle, Corinne Simone and Sall, Fatimata Bintou and Restrepo, Camilo Gomez and Tan, Cecilio and Sitali, Norman and Saunders, Matthew J},
  title = {The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {4},
  pages = {838--845},
  doi = {10.1093/cid/ciaf035}
}
Kostenlos starten →